RECRUITING

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Talk to us

Conditions

Dry Eye DiseaseoGVHD

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Evaluate and study the immunologic changes to the ocular surface in cancer patients.

Official Title

2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study

Quick Facts

Study Start:2022-04-27
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04946721

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
  2. * The patient must be able to understand and sign and date the informed consent form approved by the IRB.
  1. * Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
  2. * Inability or refusal to provide informed consent.
  3. * History of ocular surgery (except refractive surgery or cataract surgery)

Contacts and Locations

Study Contact

Sarah B Sunshine, MD
CONTACT
667-214-1292
ssunshine@som.umaryland.edu
Patricia Lesho
CONTACT
410-328-2577
plesho@umm.edu

Principal Investigator

Sarah Sunshine, MD
PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore

Study Locations (Sites)

Geenebaum Cancer Center, University of Maryland Medical Center
Baltimore, Maryland, 21201
United States

Collaborators and Investigators

Sponsor: University of Maryland, Baltimore

  • Sarah Sunshine, MD, PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-27
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2022-04-27
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Dry Eye Disease
  • oGVHD